{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:40:56Z","timestamp":1793176856030,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007859","name":"University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007859","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.xphs.2022.12.008","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T02:37:42Z","timestamp":1671158262000},"page":"1089-1107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Biorelevant Dissolution Method Considerations for the Appropriate Evaluation of Amorphous Solid Dispersions: are Two Stages Necessary?"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-3549","authenticated-orcid":false,"given":"Zhaoxian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0218-6382","authenticated-orcid":false,"given":"Hao","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahnee J.","family":"Dening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-6577","authenticated-orcid":false,"given":"Michael J.","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.12.008_bib0001","doi-asserted-by":"crossref","DOI":"10.1023\/A:1007516718048","article-title":"What is the true solubility advantage for amorphous pharmaceuticals?","author":"Hancock","year":"2000","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.008_bib0002","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.ddtec.2011.10.002","article-title":"The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate","volume":"9","author":"Van Den Mooter","year":"2012","journal-title":"Drug Discov Today: Technol"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.008_bib0003","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/mp500660m","article-title":"Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions","volume":"12","author":"Chen","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2016.06.024","article-title":"Theoretical and experimental investigation of drug-polymer interaction and miscibility and its impact on drug supersaturation in aqueous medium","author":"Baghel","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0005","article-title":"Balancing solid-state stability and dissolution performance of lumefantrine amorphous solid dispersions: the role of polymer choice and drug\u2013polymer interactions","author":"Hiew","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-409X(01)00098-9","article-title":"Amorphous pharmaceutical solids: preparation, characterization and stabilization","author":"Yu","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2022.12.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/jps.22074","article-title":"Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development","author":"Qian","year":"2010","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.008_bib0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jps.23358","article-title":"Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-impact of different polymers","volume":"102","author":"Wegiel","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2020.04.014","article-title":"Impact of hypromellose acetate succinate grade on drug amorphous solubility and in vitro membrane transport","author":"Ueda","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","author":"Brouwers","year":"2009","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.008_bib0011","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.molpharmaceut.5b00837","article-title":"Improving oral bioavailability of sorafenib by optimizing the \u201cspring\u201d and \u201cparachute\u201d based on molecular interaction mechanisms","volume":"13","author":"Liu","year":"2016","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2022.12.008_bib0012","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1007\/s11095-015-1709-z","article-title":"Phase behavior of resveratrol solid dispersions upon addition to aqueous media","volume":"32","author":"Wegiel","year":"2015","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.008_bib0013","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jps.23031","article-title":"Assessing the performance of amorphous solid dispersions","volume":"101","author":"Newman","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1080\/17425247.2017.1230099","article-title":"Supersaturation and crystallization: non-equilibrium dynamics of amorphous solid dispersions for oral drug delivery","author":"Kawakami","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"10.1016\/j.xphs.2022.12.008_bib0015","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1002\/jps.24112","article-title":"Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution","volume":"103","author":"Takeuchi","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-020-0417-8","article-title":"Selection of in vivo predictive dissolution media using drug substance and physiological properties","author":"Mudie","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2022.12.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1021\/mp8000793","article-title":"Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview","author":"Friesen","year":"2008","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2022.12.008_bib0018","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/acs.molpharmaceut.7b00338","article-title":"Impact of drug-rich colloids of itraconazole and HPMCAS on membrane flux in vitro and oral bioavailability in rats","volume":"14","author":"Stewart","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","author":"Galia","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2022.12.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2016.06.006","article-title":"Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: where are we now and what are the gaps?","author":"Flanagan","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0021","doi-asserted-by":"crossref","DOI":"10.1021\/mp400426f","article-title":"Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy","author":"Mathias","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0022","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-019-2698-0","article-title":"Utilization of in vitro, in vivo and in silico tools to evaluate the pH-dependent absorption of a BCS class II compound and identify a pH-effect mitigating strategy","author":"Gesenberg","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2022.12.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.0c01207","article-title":"In vitro sensitivity analysis of the gastrointestinal dissolution profile of weakly basic drugs in the stomach-to-intestine fluid changing system: explanation for variable plasma exposure after oral administration","author":"Takagi","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.7b00198","article-title":"Validation of dissolution testing with biorelevant media: an OrBiTo study","author":"Mann","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2015.05.013","article-title":"In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib","author":"Tsume","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2022.12.008_bib0026","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.xphs.2016.02.020","article-title":"The evaluation of in vitro drug dissolution of commercially available oral dosage forms for itraconazole in gastrointestinal simulator with biorelevant media","volume":"105","author":"Matsui","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0027","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejps.2018.01.039","article-title":"Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): an in vitro-in silico-in vivo approach","volume":"115","author":"Hens","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0028","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2017.02.042","article-title":"The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: gastrointestinal Simulator (GIS)","volume":"102","author":"Tsume","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/jps.24423","article-title":"Trends in the precipitation and crystallization behavior of supersaturated aqueous solutions of poorly water-soluble drugs assessed using synchrotron radiation","author":"Raina","year":"2015","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.008_bib0030","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s11095-013-1216-z","article-title":"Classification of the crystallization behavior of amorphous active pharmaceutical ingredients in aqueous environments","volume":"31","author":"Van Eerdenbrugh","year":"2014","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.008_bib0031","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.xphs.2018.11.006","article-title":"Molecular drivers of crystallization kinetics for drugs in supersaturated aqueous solutions","volume":"108","author":"Alhalaweh","year":"2019","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.008_bib0032","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.xphs.2017.10.002","article-title":"Monitoring the phase behavior of supersaturated solutions of poorly water-soluble drugs using fluorescence techniques","volume":"107","author":"Tres","year":"2018","journal-title":"J Pharm Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2022.12.008_bib0033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijpharm.2018.03.038","article-title":"Mechanistic understanding of the phase behavior of supersaturated solutions of poorly water-soluble drugs","volume":"543","author":"Tres","year":"2018","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.008_bib0034","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1081\/DDC-100105180","article-title":"The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug\/polymer blends for melt extrusion","volume":"27","author":"Forster","year":"2001","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.008_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/pharmaceutics10040164","article-title":"The influence of polymers on the supersaturation potential of poor and good glass formers","volume":"10","author":"Blaabjerg","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2022.12.008_bib0036","unstructured":"USP. The dissolution procedure: development and validation. United States Pharmacopeia and National Formulary. Published online 2015."},{"key":"10.1016\/j.xphs.2022.12.008_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2019.05.008","article-title":"Possibilities and limiting factors for the use of dissolution as a quality control tool to detect presence of crystallinity for amorphous solid dispersions: an experimental and modeling investigation","author":"Hermans","year":"2019","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2022.12.008_bib0038","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.xphs.2016.03.024","article-title":"Non-sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems","volume":"105","author":"Sun","year":"2016","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2022.12.008_bib0039","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1021\/cg301679h","article-title":"Liquid-liquid phase separation in highly supersaturated aqueous solutions of poorly water-soluble drugs: implications for solubility enhancing formulations","volume":"13","author":"Ilevbare","year":"2013","journal-title":"Cryst Growth Des"},{"issue":"8","key":"10.1016\/j.xphs.2022.12.008_bib0040","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.xphs.2020.04.023","article-title":"Biorelevant two-stage in vitro testing for rDCS classification and in PBPK modeling\u2013case example ritonavir","volume":"109","author":"Fiolka","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2018.09.014","article-title":"Phase separation of supersaturated solution created from amorphous solid dispersions: Relevance to oral absorption","author":"Kawakami","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091424","article-title":"Eudragit\u00ae: A versatile family of polymers for hot melt extrusion and 3D printing processes in pharmaceutics","author":"Dos Santos","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2022.12.008_bib0043","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/acs.molpharmaceut.5b00798","article-title":"Improved release of celecoxib from high drug loading amorphous solid dispersions formulated with polyacrylic acid and cellulose derivatives","volume":"13","author":"Xie","year":"2016","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2022.12.008_bib0044","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1021\/cg301447d","article-title":"Maintaining supersaturation in aqueous drug solutions: impact of different polymers on induction times","volume":"13","author":"Ilevbare","year":"2013","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.xphs.2022.12.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.6b01116","article-title":"A systematic study of molecular interactions of anionic drugs with a dimethylaminoethyl methacrylate copolymer regarding solubility enhancement","author":"Saal","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0046","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5b00979","article-title":"Indomethacin-Kollidon VA64 extrudates: a mechanistic study of pH-dependent controlled release","author":"Tres","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.115828","article-title":"Hypromellose acetate succinate based amorphous solid dispersions via hot melt extrusion: Effect of drug physicochemical properties","volume":"233","author":"Sarabu","year":"2020","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.xphs.2022.12.008_bib0048","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.9b01063","article-title":"Investigation of within-tablet dynamics for extended release of a poorly soluble basic drug from hydrophilic matrix tablets using ATR-FTIR imaging","author":"Zahoor","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3549(15)00176-8","article-title":"Development of pH-independent drug release formulation using lipocalin-type prostaglandin D synthase","author":"Mizoguchi","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0050","first-page":"155","article-title":"Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: history, methodology and applications","author":"Augustijns","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.12.008_bib0051","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.2c00124","article-title":"Mechanisms and extent of enhanced passive permeation by colloidal drug particles","author":"Narula","year":"2022","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2022.12.008_bib0052","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1021\/acs.molpharmaceut.0c00599","article-title":"Toward developing discriminating dissolution methods for formulations containing nanoparticulates in solution: the impact of particle drift and drug activity in solution","volume":"17","author":"Arce","year":"2020","journal-title":"Mol Pharm"},{"issue":"22","key":"10.1016\/j.xphs.2022.12.008_bib0053","doi-asserted-by":"crossref","first-page":"13053","DOI":"10.1039\/C6RA28676C","article-title":"Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement","volume":"7","author":"He","year":"2017","journal-title":"RSC Adv"},{"issue":"1","key":"10.1016\/j.xphs.2022.12.008_bib0054","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1515\/revac-2022-0032","article-title":"Review of characteristics and analytical methods for determination of indomethacin","volume":"41","author":"Dandi\u0107","year":"2022","journal-title":"Rev Anal Chem"},{"issue":"6","key":"10.1016\/j.xphs.2022.12.008_bib0055","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1021\/acs.molpharmaceut.7b00121","article-title":"Development of a biorelevant, material-sparing membrane flux test for rapid screening of bioavailability-enhancing drug product formulations","volume":"14","author":"Stewart","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.12.008_bib0056","first-page":"143","article-title":"Could the small molecules such as amino acids improve aqueous solubility and stabilize amorphous systems containing Griseofulvin?","author":"Fran\u00e7a","year":"2020","journal-title":"Eur J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922005755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:40:24Z","timestamp":1758361224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922005755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0022354922005755"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.008","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biorelevant Dissolution Method Considerations for the Appropriate Evaluation of Amorphous Solid Dispersions: are Two Stages Necessary?","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}